Member Info for Cashintime

Happy new year to all Poolbeg holders.
This will have to be a year of deals for Poolbeg Pharma in what be be a tough environment for the markets in the first 2 quarters minimum. Even Nasdaq is down 33% for 2022 so it will have lots of "fallen angels" as CF put it.
JP Morgan get together next week for a few days where we will be hoping to do the groundwork for a deal or two. MMs seem very quick to drop us back to these levels from IPO price for whatever reason. The company has been squeaky clean in its strategy and delivery. Maybe we need interest from the bigger buyers and we may just get that from Nasdaq listing.

We all hope good quality news is coming as we are actively attempting to attract the partnership for multiple high quality products that have been vetted by a highly impressive collection of industry experts at Poolbeg Pharma.
In this type of play one hit on goal can bring in multiples of our present market cap.
I think that we have not got fair value here from the market at the moment.
Our flagship product POLB 001 could just be the one. We will know more when the data has been gone through. I think Poolbeg didn't want to make early exaggerated claims about its efficacy without clinically ticking all boxes dotting all I's and crossing all the T's to the satisfaction of an acceptable industry standard. Our time will come and will the right deal the market will be unable to hold us back.

https://youtu.be/M0B5hDqgv1g

2023, Jeremy will hit the ground running. The AI collaborated products will have the best candidates pushed forward to enter phase 1b trials. Deals will be made and American grants will be finalized.

Nice surprise when I looked in here earlier. Grabbed the opportunity and cashed out. Nice Christmas present totally un expected.
It will be a tough year for stocks and cash is always king with recession looming.

Great write up tipping Poolbeg and Hvivo. 2023 should be our year.

Sanderson has played a blinder this year. He has spent the whole year drawing over a bag of sand a day for doing absolutely nothing. We will have another raise in the new year which will create a new massive dilution and create such an overhang that the shareprice will never recover from.
He has had no communication to his shareholders this year as he is ashamed to show his face and rightly so.
I can only hope that he will be dumped at next year's AGM. He should do the honourable thing now and tender his resignation as he comes to terms with his inability to run this company. There has been lots of deceit and fake promising going on here for years.
He in his leadership has eroded all shareholder value. He is incapable.

All positive for Poolbeg in that podcast. The hatches will be lifted here yet as we get on the radar. I think getting on Nasdaq will be beneficial for us here as we hit a broader market.

Poolbeg are building a nice stable of products. It was always going to have a model of partnership with big Pharma to bring these products along the next stage. Now we have the ability as stated to have multiple shots on goal and I feel 2023 will be our year. It is a pity that we cannot stay above the IPO price but entry into the Nasdaq may just create the liquidity that we yearn for. It will open us up to the deep American pockets who will hopefully take a longer view unlike the AIM wild west where punters want everything tomorrow. It is a great company with fantastic communication to its shareholders with an impressive model and team onboard. They have the contacts in the industry with talks in motion already. JP Morgan get together in the new year may just open the door and lift the hatches here. A happy Christmas to all LTHs in Poolbeg.

Looking forward to hearing more of these new AI generated targets. Another time line hit by this impressive team with this collaboration with One three. This adds more products to our growing stable.
Will the market respond accordingly

The question is will one three AI results lift us out of this slump.

We never got to retire to the Bahamas.
No oil there either. Don't remind me. That cost me a few pound.

Come on Sanderson. Wake up and communicate with the shareholders. Don't make us wait until the AGM to hold you to account and force the answers out of you. If your wages were performance linked things would not be too good for you now.

Pity this board is getting infested at the moment causing distruption,doubt,launching personal attacks on other board members. Are they just nuuters,paid trolls working on somebody else's behalf of just short term trade merchants looking to suit their own agenda I don't know. When they launch the personal attacks it is easy to spot who they are. We all want the shareprice up but sometimes these people want it down. They do it by creating distaste and doubt. Horrible life to lead.

Excellent communication from Jeremy as usual. It is refreshing to have somebody who is openly honest working tirelessly on behalf of the shareholders. Why can't the market give this company a break. Hope to see this when we get the AI new targets before year's end. Welcome above to the Professor. I would say he will need to keep on a tight budget. Promising technology and ready to go. Shareprice could well recover by year end.

Silent Steve is really adding to shareholder value the past year. Is he even on the planet anymore.

Lots of news this December coming with the one three AI drug targets. Jigsaw certainly falling in place.
Soon news re Nasdaq listing. CF in the background doing a deal I feel.

https://youtu.be/Ulg-5O2rIEo
A bit of an update from Jeremy with a bit of enthusiasm.

Sorry links not working out for me today.

It is clear that Jeremy has to inform us a bit better on the preliminary LPS study results. Why didn't he state that he was delighted to progress POLB 001 to the next stage. He said he would be looking for a Pharma partner but the wording of the RNS was generally dull. The vox interview would lead me to believe that all is going to plan as expected. Strange really.
Https://www.**********.co.uk/articles/jeremy-skillington-of-poolbeg-pharma-polb-001-lps-human-challenge-clinical-trial-successfully-completed-155582b